全球肝炎市場 - 到2017年為止的預測:C型肝炎強有力的開發平台，多數的策略性整合及成本效益高的療法推動市場成長

全球肝炎市場 - 到2017年為止的預測:C型肝炎強有力的開發平台，多數的策略性整合及成本效益高的療法推動市場成長 是由出版商GBI Research在2012年01月所出版的。 這份英文市場調查報告書包含Pages: 114 價格從美金3500起跳。

簡介

全球肝炎治療藥及疫苗市場在2010年收益約為47億美金，預測到2017年將達到86億美金的規模。

本報告以美國、歐洲五國、日本的肝炎市場為調查對象，預測到2017年為止的治療法使用模式、銷售額、價格、出貨量、以及主要治療藥品部門相關的各地區預測，主要企業的競爭基準、合併、收購、授權契約等形成全球市場的要素分析，為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 市場概要

• 全球肝炎治療藥物/疫苗市場
• 全球肝炎治療藥物市場收益預測
• 肝炎市場發展因素
• 肝炎市場阻礙因素
• 全球肝炎治療藥物市場上學名藥的市場佔有率

第4章 治療情形

• A型/B型肝炎的疫苗市場概要
• B型肝炎的治療藥物市場
• C型肝炎的治療藥物市場

第5章 各地區情形

• 各地區分析
• 美國的肝炎治療藥物市場
• 歐洲的肝炎治療藥物市場上前五名國家
• 日本的肝炎治療藥物市場

第6章 開發平台分析

• 臨床開發中的有潛力B型肝炎疫苗的分子簡介
• 臨床開發中的有潛力B型肝炎治療藥物的分子簡介
• 臨床開發中的有潛力C型肝炎治療藥物的分子簡介

第7章 競爭情形

• 市場佔有率分析:肝炎
• 競爭分析

第8章 策略性整合

• 合併·收購
• R&D授權契約
• 共同開發契約

第9章 附錄

圖表

目錄

Summary

GBI Research has found that the global hepatitis market is one of the fast growing markets of the pharmaceutical industry. The approval of potential new drugs and combinational therapies with significant efficacy, safety and resistance profiles will fuel the rapid uptake of drugs in the near future. Limitations of the current standard care therapy for hepatitis include high incidence of adverse events, long duration of treatment, suboptimal patient compliance and the lack of efficacy in specific genotypes. This has increased interest in developing novel products able to potentially counter this unmet need.

Scope

• Annualized market data for the hepatitis market from 2002 to 2010, forecast forward to 2017.
• Analysis of the leading segments, including hepatitis A, hepatitis B and hepatitis C.
• Analysis of the hepatitis market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
• Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
• Key drivers and barriers that have a significant impact on the market.
• Coverage of pipeline molecules in various Phases of drug development.
• Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.
• Key M&A activities, licensing agreements that have taken place between 2009 and mid-2011 in the global hepatitis market.

Reasons to buy

• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
• Develop key strategic initiatives by understanding the key focus areas of leading companies.
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

GBI Research's new report, “Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market”, provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The global hepatitis therapeutics and vaccines market generated approximately $4.7 billion in 2010. The market is anticipated to reach revenues of approximately $8.6 billion by 2017, growing at a Compound Annual Growth Rate of 9% between 2010 and 2017. From 2002 to 2010, the market grew at a CAGR of 3.8%.

The hepatitis C market is expected to grow at a high rate during the forecast period whereas the hepatitis B market will witness low growth.

The target patient base of the hepatitis market includes newly infected or diagnosed hepatitis patients, non-responders and patients who have discontinued treatment. As a result, there is a huge unmet need in the market. The high cost of therapy has also proved a major concern.

The current hepatitis C pipeline does offer some promising novel products, and as a result the overall growth of the global hepatitis market is expected to show a moderate increase in the future.

The global hepatitis vaccines market is expected to increase by 2017. It is expected to grow at a higher rate between 2010 and 2017 than between 2002 and 2010. This can be primarily attributed to the introduction of novel vaccines in the market, such as Heplisav and spi-VEC among others.

The current hepatitis pipeline contains 237 projects across the different developmental stages. Hepatitis B and C currently account for more than two-thirds of the total hepatitis market and are the key therapy areas of focus in the current pipeline, of which they account for approximately 98%. More than 50% of the projects for hepatitis B and hepatitis C are in the early stages of research, which suggests that the market can expect novel drugs in the future.

The hepatitis C therapeutics pipeline has four molecules in Phase III, and the introduction of novel therapies will be a driver for the market. Products such as boceprevir, zalbin, telaprevir and RG7128 are already in the clinical development stage or approved by FDA, and their launch will reinforce the market growth.

The hepatitis B pipeline has 10 molecules in Phase III but most are combination therapies. Phase II is also dominated by combination therapies. The pipeline for hepatitis B lacks novel drugs and is therefore weak. The pipeline portfolio for hepatitis A is also weak, with four programs in various developmental stages. The high growth of the hepatitis C therapeutics market during the forecast period will support the global hepatitis market as a whole.

Between 2009 and mid-2011, the hepatitis sector witnessed numerous strategic consolidations which are expected to result in high growth in the near future. There have been increasing numbers of licensing agreements for drugs in the hepatitis C pipeline portfolio, primarily due to the market's high growth potential. The hepatitis C market also has the highest number of molecules in the pipeline portfolio, indicating a strong future. This will facilitate more Mergers and Acquisitions (M&As) and licensing agreements.

A total of 17 major licensing deals took place between 2010 and mid-2011 in the hepatitis market, including in the field of hepatitis B and hepatitis C therapeutics. Hepatitis B therapeutics accounted for 61% of deals in licensing agreements. This is the main area of focus for companies active in the hepatitis therapeutics market due to the potential for growth. Approximately 39% of deals were for hepatitis C therapeutics.

1. Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2. Global Hepatitis Market - Introduction

• 2.1 GBI Research Report Guidance

3. Global Hepatitis Market - Market Overview

• 3.1 Introduction
• 3.2 Global Hepatitis Therapeutics and Vaccines Market
• 3.3 Revenue Forecasts for the Global Hepatitis Therapeutics Market
  • 3.3.1 Revenue
  • 3.3.2 Annual Cost of Therapy
  • 3.3.3 Treatment Usage Patterns
• 3.4 Hepatitis Market Drivers
  • 3.4.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline
  • 3.4.2 Promising Developments in Hepatitis C Pipeline
  • 3.4.3 Steady Increase in Prescription Population
• 3.5 Hepatitis Market Restraints
  • 3.5.1 Hepatitis Rarely Recognized during the Early Stages of the Disease
  • 3.5.2 Low Treatment Seeking Population
  • 3.5.3 Loss of Exclusivity Protection in Hepatitis B Market
• 3.6 Generic Share in the Global Hepatitis Therapeutics Market

4. Global Hepatitis Market - Therapeutic Landscape

• 4.1 Introduction
  • 4.1.1 Hepatitis A
  • 4.1.2 Hepatitis B
  • 4.1.3 Hepatitis C
• 4.2 Overview of Hepatitis A and B Vaccines Market
  • 4.2.1 Revenue
• 4.3 Hepatitis B Therapeutics Market
  • 4.3.1 Revenue
  • 4.3.2 Annual Cost of Therapy
  • 4.3.3 Treatment Usage Patterns
  • 4.3.4 Geographical Segmentation
• 4.4 Hepatitis C Therapeutics Market
  • 4.4.1 Revenue
  • 4.4.2 Annual Cost of Therapy
  • 4.4.3 Treatment Usage Pattern
  • 4.4.4 Geographical Segmentation

5. Global Hepatitis Market - Geographical Landscape

• 5.1 Geographical Break-up
• 5.2 The US Hepatitis Therapeutics Market
  • 5.2.1 Revenue
  • 5.2.2 Annual Cost of Therapy
  • 5.2.3 Treatment Usage Patterns
• 5.3 Top Five Countries in Europe Hepatitis Therapeutics Market
  • 5.3.1 Revenue
  • 5.3.2 Annual Cost of Therapy
  • 5.3.3 Treatment Usage Patterns
• 5.4 Japan Hepatitis Therapeutics Market
  • 5.4.1 Revenue
  • 5.4.2 Annual Cost of Therapy
  • 5.4.3 Treatment Usage Patterns

6. Global Hepatitis Market - Pipeline Analysis

• 6.1 Introduction
  • 6.1.1 Research and Development Pipeline - Hepatitis A Vaccines
  • 6.1.2 Research and Development Pipeline - Hepatitis B Therapeutics
  • 6.1.3 Research and Development Pipeline - Hepatitis B Vaccines
  • 6.1.4 Research and Development Pipeline - Hepatitis C Therapeutics
• 6.2 Molecule Profile for Promising Vaccines for Hepatitis B under Clinical Development
  • 6.2.1 Heplisav
  • 6.2.2 Spi-VEC
• 6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development
  • 6.3.1 Entecavir plus Adefovir Combination Therapy
  • 6.3.2 Tenofovir plus Emtricitabine Combination Therapy
  • 6.3.3 Pegylated Interferon Alfa-2a + Adefovir
• 6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development
  • 6.4.1 Tenofovir + Emtricitabine Combination Therapy
  • 6.4.2 Zalbin (albinterferon alfa-2b, Joulferon)
  • 6.4.3 RG 7128

7. Global Hepatitis Market - Competitive Landscape

• 7.1 Market Share Analysis: Hepatitis
• 7.2 Competitive Profiling
  • 7.2.1 Merck & Co., Inc.
  • 7.2.2 F. Hoffmann-La Roche Ltd.
  • 7.2.3 GlaxoSmithKline plc

8. Global Hepatitis Market - Strategic Consolidations

• 8.1 Mergers and Acquisitions
  • 8.1.1 Overview
  • 8.1.2 Summary of M&A Deals (2010-2011)
• 8.2 R&D Licensing Agreements
  • 8.2.1 Summary of Licensing Deals (2010-2011)
• 8.3 Co-Development Deals

9. Global Hepatitis Market - Appendix

• 9.1 Market Definitions
• 9.2 Abbreviations
• 9.3 Research Methodology
  • 9.3.1 Coverage
  • 9.3.2 Secondary Research
  • 9.3.3 Primary Research
• 9.4 Therapeutic Landscape
  • 9.4.2 Market Size by Geography
• 9.5 Geographical Landscape
• 9.6 Pipeline Analysis
• 9.7 Competitive Landscape
  • 9.7.1 Expert Panel Validation
• 9.8 Contact Us
• 9.9 Disclaimer

• Table 1: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2002-2010
• Table 2: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2010-2017
• Table 3: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2010
• Table 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2010-2017
• Table 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010
• Table 6: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
• Table 7: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern ('000s), 2002-2010
• Table 8: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern ('000s), 2010-2017
• Table 9: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2010
• Table 10: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2010-2017
• Table 11: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2010
• Table 12: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2010-2017
• Table 13: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010
• Table 14: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
• Table 15: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010
• Table 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Patterns, 2010-2017
• Table 17: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010
• Table 18: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017
• Table 19: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2010
• Table 20: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2010-2017
• Table 21: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010
• Table 22: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
• Table 23: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010
• Table 24: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2010-2017
• Table 25: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2002-2010
• Table 26: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2010-2017
• Table 27: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2010
• Table 28: Hepatitis Market, Global, Revenue by Geography ($m), 2010-2017
• Table 29: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2010
• Table 30: Hepatitis Therapeutics Market, The US, Revenue Forecasts ($m),2010-2017
• Table 31: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2010
• Table 32: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017
• Table 33: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern ('000s), 2002-2010
• Table 34: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern ('000s), 2010-2017
• Table 35: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2010
• Table 36: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2010-2017
• Table 37: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
• Table 38: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
• Table 39: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern ('000s), 2002-2010
• Table 40: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern ('000s), 2010-2017
• Table 41: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2010
• Table 42: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2010-2017
• Table 43: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010
• Table 44: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017
• Table 45: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern ('000s), 2002-2010
• Table 46: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern ('000s), 2010-2017
• Table 47: Hepatitis B Therapeutics Market, Global, Pipeline, 2011
• Table 48: Hepatitis B Vaccines Market, Global, Pipeline, 2011
• Table 49: Hepatitis C Therapeutics Market, Global, Pipeline, 2011

• Figure 1: Hepatitis Market, Global, Drivers and Restraints, 2011
• Figure 2: Hepatitis Market, Hepatitis Treatment Flow Pathway, 2017
• Figure 3: Hepatitis Market, Global Therapeutics and Vaccines Market, Revenues ($m), 2002-2017
• Figure 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2017
• Figure 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017
• Figure 6: Hepatitis Therapeutics Market, Global, Therapeutic Usage Pattern, 2002-2017
• Figure 7: Hepatitis Therapeutics Market, Global, Diseased Population ('000s), 2002-2017
• Figure 8: Hepatitis Therapeutics Market, Global, Treatment Seeking Population ('000s), 2002-2017
• Figure 9: Hepatitis Therapeutics Market, Global, Diagnosed Population ('000s), 2002-2017
• Figure 10: Hepatitis Therapeutics Market, Global, Prescription Population ('000s), 2002-2017
• Figure 11: Hepatitis Therapeutics Market, Global, Branded and Generic Share (%), 2010-2017
• Figure 12: Hepatitis Market, Global, Hepatitis B-Genotypes Based on Geographic Origin
• Figure 13: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2017
• Figure 14: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2017
• Figure 15: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017
• Figure 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017
• Figure 17: Hepatitis B Therapeutics Market, Global, Diseased Population ('000s), 2002-2017
• Figure 18: Hepatitis B Therapeutics Market, Global, Treatment Seeking Population ('000s), 2002-2017
• Figure 19: Hepatitis B Therapeutics Market, Global, Diagnosed Population ('000s), 2002-2017
• Figure 20: Hepatitis B Therapeutics Market, Global, Prescription Population ('000s), 2002-2017
• Figure 21: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017
• Figure 22: Hepatitis B Therapeutics Market, Global, Geography Benchmarking, 2010
• Figure 23: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2017
• Figure 24: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017
• Figure 25: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017
• Figure 26: Hepatitis C Therapeutics Market, Global, Diseased Population ('000s), 2002-2017
• Figure 27: Hepatitis C Therapeutics Market, Global, Treatment Seeking Population ('000s), 2002-2017
• Figure 28: Hepatitis C Therapeutics Market, Global, Diagnosed Population ('000s), 2002-2017
• Figure 29: Hepatitis C Therapeutics Market, Global, Prescription Population ('000s), 2002-2017
• Figure 30: Hepatitis C Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017
• Figure 31: Hepatitis C Therapeutics Market, Global, Geography Benchmarking, 2010
• Figure 32: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2017
• Figure 33: Hepatitis Market, Global, Geography Benchmarking, 2010 and 2017
• Figure 34: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2017
• Figure 35: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2017
• Figure 36: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern, 2002-2017
• Figure 37: Hepatitis Therapeutics Market, The US, Diseased Population ('000s), 2002-2017
• Figure 38: Hepatitis Therapeutics Market, The US, Treatment Seeking Population ('000s), 2002-2017
• Figure 39: Hepatitis Therapeutics Market, The US, Diagnosed Population ('000s), 2002-2017
• Figure 40: Hepatitis Therapeutics Market, The US, Prescription Population ('000s), 2002-2017
• Figure 41: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2017
• Figure 42: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
• Figure 43: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern, 2002-2017
• Figure 44: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population ('000s), 2002-2017
• Figure 45: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population ('000s), 2002-2017
• Figure 46: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population ('000s), 2002-2017
• Figure 47: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population ('000s), 2002-2017
• Figure 48: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2017
• Figure 49: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017
• Figure 50: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 2002-2017
• Figure 51: Hepatitis Therapeutics Market, Japan, Diseased Population ('000s), 2002-2017
• Figure 52: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population ('000s), 2002-2017
• Figure 53: Hepatitis Therapeutics Market, Japan, Diagnosed Population ('000s), 2002-2017
• Figure 54: Hepatitis Therapeutics Market, Japan, Prescription Population ('000s), 2002-2017
• Figure 55: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011
• Figure 56: Hepatitis Market, Global, R&D Pipeline by Phase (%), 2011
• Figure 57: Hepatitis B Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011
• Figure 58: Hepatitis B Vaccines Market, Global, R&D Pipeline by Phase (%), 2011
• Figure 59: Hepatitis C Therapeutics Market Global, R&D Pipeline by Phase (%), 2011
• Figure 60: Hepatitis B and Hepatitis C Therapeutics Market, Global, Market Share of Top Players (%), 2010
• Figure 61: Hepatitis Vaccines Market, Global, Market Share of Top Players (%), 2010
• Figure 62: Hepatitis Market, Merck & Co., Inc., SWOT Analysis, 2011
• Figure 63: Hepatitis Market, F. Hoffmann-La Roche Ltd., SWOT Analysis, 2011
• Figure 64: Hepatitis Market, GlaxoSmithKline plc, SWOT Analysis, 2011
• Figure 65: Hepatitis Therapeutics and Vaccines Market, Global, M&A Deals by Geography (%), 2011
• Figure 66: Hepatitis Therapeutics and Vaccines Market, M&A Deals by Type (%), 2011
• Figure 67: Hepatitis Market, Global, Major Licensing Agreements by Indication (%), 2011
• Figure 68: Hepatitis Market, Global, Major Co-Development Deals by Indication (%), 2011
• Figure 69: GBI Research Market Forecasting Model

相關商品

感染疾病相關市場調查報告書

抗病毒藥物的市場 (∼2017年):抵消HIV治療藥物市場上非專利藥品影響的高價的複合治療藥物的接受度增加
Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
價格 : US $ 3500
出版日期 : 2012年04月

抗病毒療法：技術、市場、企業
Antiviral Therapeutics - technologies, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

皰疹市場(∼2018年):為求與其他競爭公司有所差異的非專利藥品，而採用新的給藥技術
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies
價格 : US $ 3500
出版日期 : 2012年04月

GBI Research發行的製藥相關市場調查報告書

學名藥的價格設定與回本:歐洲的緊縮政策與醫療費抑制的創新主導型製藥企業的壓力

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure

價格 : US $ 3500

出版日期 : 2012年04月

到2018年為止的開發業務受託機關 (CRO) 市場:研究能力強化和臨床開發計劃發展的官民合作關係

Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs

價格 : US $ 3500

出版日期 : 2012年04月

到2018年為止的醫藥品受託製造廠商 (CMO) 市場:成本優勢和質量標準提高的信賴建立和對亞洲CMO的外國投資的促進

Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs

價格 : US $ 3500

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!